Japan’s raw deal shows India needs to cure Delhi belly

Two soured deals are NTT Docomo Inc.’s $2.2 billion investment in Tata Group, and the $4.6 billion Daiichi Sankyo Co. deal to buy Ranbaxy Laboratories Ltd


The Docomo dispute might be quicker to resolve as Ratan Tata is reportedly keen to solve it. Photo: Reuters
The Docomo dispute might be quicker to resolve as Ratan Tata is reportedly keen to solve it. Photo: Reuters

Singapore: Japan Inc. is getting a raw deal in India. Some of its high-profile investments in the country have created more wealth for arbitration lawyers in London and Singapore than they have for shareholders. Those who were expecting great things from the bromance between Japanese prime minister Shinzo Abe and his Indian counterpart Narendra Modi have reasons to be disappointed.

Two soured deals are NTT Docomo Inc.’s $2.2 billion investment in an Indian wireless venture with the Tata Group, and the $4.6 billion Daiichi Sankyo Co. shelled out to buy Ranbaxy Laboratories Ltd, a generic drugmaker. Almost a decade on, the Japanese companies have won claims to compensation via international arbitration proceedings, but in neither case is there any sign of a check in the mail.

The Docomo dispute might be quicker to resolve. Ratan Tata, who recently reclaimed control of the conglomerate in a boardroom putsch, is reportedly keen to settle. It was he who had promised to buy out Docomo at a 50% loss on its original investment in five years.

But when the Japanese tried to exercise their put option in 2014, the Indian group contended that in local law, a guaranteed exit price would become unwelcome foreign debt masquerading as equity, therefore, the Tatas could neither honour their commitment, nor fulfil the arbitration award the Japanese company won last year in London.

ALSO READ: Tata-Mistry ties strained further with Tata Motors 2015 rights issue: Affidavit

Daiichi Sankyo’s misery began when it acquired Ranbaxy from brothers Malvinder Singh and Shivinder Singh in 2008. Shortly after, US regulators barred more than 30 drugs made at two of the Indian company’s plants and also halted reviews of new products at one of the factories because the company had falsified data.

In May last year, the Singapore International Arbitration Centre awarded Daiichi a $376 million claim against the Singh brothers for suppressing facts, which had cost Ranbaxy an expensive settlement with the US regulator. Japan Inc.’s total outbound mergers and acquisitions (M&A) last year stood at $79.7 billion.

That victory doesn’t mean much. The siblings are contending that the Singapore award is invalid under Indian law. Daiichi, which has already exited India at a loss, is now hoping the courts there will stop the Singh brothers from selling a stake in their hospital chain Fortis Healthcare Ltd before settling their claim.

Earlier this month, Mint reported that KKR & Co. was in talks with the brothers to buy Fortis, which has an enterprise value of $1.5 billion. In a new twist, Daiichi claims it just found out that one of the Singh brothers’ investment companies it sued to recover the money from no longer exists.

The longer such wrangles linger, the stronger the impression that India’s local laws make it impossible to settle commercial disputes with foreigners. Japanese firms aren’t the most ambitious of dealmakers in emerging markets anyway.

Their total acquisitions in Brazil, Russia, India and China have amounted to just $25 billion over the past six years, of which India’s share has been $4.4 billion. By contrast, American companies spent $5.1 billion shopping in India last year.

Abe wants the coyness to end and hopes for a big role in India’s railway modernization. However, for long-gestation infrastructure projects, sanctity of contract enforcement will be even more important. New Delhi’s tax regime is already a minefield. If Indian partners and the local law keep serving up unpalatable outcomes, then whatever appetite Japanese companies have could turn into a bellyache. Bloomberg

More From Livemint